Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience

被引：0
|
作者：
Omarini, C. [1 ]
Medici, G. [1 ]
Guaitoli, G. [1 ]
Iattoni, E. [1 ]
Moscetti, L. [1 ]
Balduzzi, S. [1 ]
Cascinu, S. [1 ]
Piacentini, F. [1 ]
机构：
[1] Univ Modena Policlin, Modena, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw337.55
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
F55
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of pertuzumab for HER2 positive metastatic breast cancer: a single institution experience
    Hara, Fumikata
    Aogi, Kenjiro
    Takashima, Seiki
    ANNALS OF ONCOLOGY, 2015, 26 : 141 - 141
  • [22] Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
    Abraham, Jame
    Montero, Albert J.
    Jankowitz, Rachel C.
    Salkeni, Mohamad Adham
    Beumer, Jan H.
    Kiesel, Brian F.
    Piette, Fanny
    Adamson, Laura M.
    Nagy, Rebecca J.
    Lanman, Richard B.
    Sperinde, Jeff
    Huang, Weidong
    Allegra, Carmen J.
    Srinivasan, Ashok
    Wang, Ying
    Pogue-Geile, Katherine L.
    Lucas, Peter C.
    Jacobs, Samuel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (29) : 2601 - +
  • [23] Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy
    Molinelli, Chiara
    Parisi, Francesca
    Razeti, Maria Grazia
    Arecco, Luca
    Cosso, Maurizio
    Fregatti, Piero
    Del Mastro, Lucia
    Poggio, Francesca
    Lambertini, Matteo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (03) : 241 - 250
  • [24] Real-World Analysis of the Efficacy and Adverse Events of T-DM1 in Chinese Patients With HER2-Positive Breast Cancer
    Gu, Huayan
    Zhu, Teng
    Ding, Jialing
    Yang, Zhi
    Qi, Shuangyi
    Guo, Guilong
    BREAST CANCER-TARGETS AND THERAPY, 2025, 17 : 201 - 210
  • [25] Meta-analysis of the clinical efficacy and safety of T-DM1 in the treatment of HER2-positive breast cancer
    Liu, Furong
    Li, Yuehua
    Yang, Dinghua
    Tang, Li
    Yang, Qian
    Jiang, Majiao
    Tian, Leilei
    An, Jingjing
    INDIAN JOURNAL OF CANCER, 2024, 61 (01) : 146 - 155
  • [26] Concomitant Association of T-DM1 and Radiation: An In Vitro Study on HER2 Positive Cells of Breast Cancer
    Mignot, F.
    Verrelle, P.
    Kirova, Y.
    Megnin-Chanet, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E186 - E186
  • [27] Lower response to T-DM1 in metastatic breast cancer patients with HER2 IHC score of 2 and FISH positive compared with IHC score of 3
    Yazaki, S.
    Hashimoto, J.
    Ogita, S.
    Nakano, E.
    Yamauchi, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer
    Fabi, Alessandra
    Alesini, Daniele
    Valle, Enrichetta
    Moscetti, Luca
    Caputo, Roberta
    Caruso, Michele
    Carbognin, Luisa
    Ciccarese, Mariangela
    La Verde, Nicla
    Arpino, Grazia
    Cannita, Katia
    Paris, Ida
    Santini, Daniele
    Montemurro, Filippo
    Russillo, Michelangelo
    Ferretti, Gianluigi
    Filippelli, Gianfranco
    Rossello, Rosalba
    Fabbri, Agnese
    Zambelli, Alberto
    Leonardi, Vita
    D'Ottavi, Anna Maria
    Nistico, Cecilia
    Stani, Simonetta
    Giampaglia, Marianna
    Scandurra, Giusy
    Catania, Giovanna
    Malaguti, Paola
    Giannarelli, Diana
    Cognetti, Francesco
    BREAST, 2018, 41 : 137 - 143
  • [29] Imaging HER2 in response to T-DM1 therapy in Breast Cancer Xenografts
    Massicano, Adriana
    Aweda, Tolulope
    Marquez-Nostra, Bernadette
    El Sayed, Retta
    Beacham, Rebecca
    Lapi, Suzanne
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [30] Metastatic HER2-positive Breast Cancer New Perspectives with Trastuzumab Emtansine (T-DM1)
    Satzger, Ulla
    ONKOLOGIE, 2013, 36 (09): : 525 - 525
12345